In 1956, a company called Hoechst Fedco Pharma Private Limited began manufacturing medicines in India. Seven decades, two name changes, and one radical strategic contraction later, it is Sanofi India Limited , smaller in revenue than its peak, larger in ambition, and present in one out of every three Indian households.
Most multinational pharmaceutical companies entered India in the 1990s, chasing liberalisation. Sanofi’s predecessor was already there, had been for decades. Hoechst Fedco Pharma Private Limited was incorporated in 1956, when India was nine years into independence and its pharmaceutical industry was almost entirely dependent on imports. The company set up manufacturing, hired local chemists, and began producing formulations for a country that needed them badly and could afford very little.
The corporate genealogy is tangled in the way that European industrial mergers always are. Hoechst AG merged into Aventis in 1999; Aventis merged into Sanofi in 2004. Each merger changed the name on the letterhead but not the people on the factory floor in Goa or the sales representatives calling on clinics in Tamil Nadu. By 2014, the Indian entity , now Sanofi India Limited , reported revenue of $332 million, employed 3,448 people, operated two manufacturing plants at Ankleshwar and Goa, and exported to more than 40 countries. It was, by any measure, one of the longest-running multinational pharmaceutical operations in the country.
That continuity matters. Seventy years of uninterrupted presence means seventy years of regulatory relationships, supply chain knowledge, and institutional memory about how Indian healthcare actually works , knowledge that cannot be acquired in a licensing deal or a joint venture signed last quarter.
There is a statistic that Sanofi India cites in its annual report that deserves a moment of consideration: its products are present in one out of every three Indian households. India has roughly 300 million households. One in three means approximately 100 million homes contain a Sanofi product , an allergy tablet, a pain reliever, a vitamin supplement, an insulin pen. The logistical infrastructure required to achieve that kind of penetration, across a country with 28 states, 22 official languages, and supply chains that run from metropolitan hospital pharmacies to rural medical shops accessible only by unpaved roads, is itself a form of competitive advantage.
The Goa manufacturing facility is the engine behind that reach. It produces five billion tablets and capsules annually , a volume that places it among the larger single-site pharmaceutical operations in India. The facility operates under the quality standards of Sanofi’s global manufacturing network, which means European GMP compliance applied to Indian-scale production volumes. At its peak in FY2018, the India entity employed 3,301 people and generated $405 million in revenue, exporting to more than 50 countries.
By FY2022, Sanofi India ranked among the top four multinational pharmaceutical companies operating in India, with 2,651 employees and $352 million in revenue. The therapeutic portfolio spanned diabetes, cardiology, pain management, allergy, and epilepsy. It was a broad, diversified business. And then the company decided to make it narrower.
In most industries, a company whose revenue falls from $436 million to $220 million over six years would be a cautionary tale. Sanofi India is the opposite: a case study in strategic contraction. The numbers went down because the company decided they should.
The logic came from Paris. Sanofi S.A., which owns 60.40% of the Indian subsidiary, undertook a global portfolio restructuring starting around 2019. The consumer healthcare division , the over-the-counter brands that had put Sanofi products in one-third of Indian households , was spun off. Sanofi Consumer Healthcare India Limited became a separate entity in FY2023. General medicines, the broad portfolio of cardiovascular and pain products that had been the backbone of Indian revenue for decades, were deprioritised in favour of specialty care and innovation.
What remained was leaner and more focused. By FY2025, Sanofi India reported revenue of $220.5 million , roughly half its FY2019 peak , with a workforce calibrated to the new portfolio. The Goa facility continued producing at scale, but the product mix had shifted decisively toward diabetes and specialty therapeutics. The company had traded breadth for depth, volume for value. Whether that trade pays off depends entirely on the next chapter.
India has more people living with diabetes than any country except China. The International Diabetes Federation estimates 101 million Indian adults are diabetic, with another 136 million prediabetic. These are not projections for some distant future; these are the numbers now. And within Sanofi India’s stripped-down portfolio, diabetes is the anchor.
Lantus , insulin glargine, the long-acting basal insulin that Sanofi introduced globally in 2000 , remains the franchise’s foundation in India. It was, for years, the market-leading basal insulin worldwide, generating peak global sales exceeding $7 billion before biosimilar competition arrived. In India, where insulin penetration among diagnosed diabetics remains far lower than in Western markets, Lantus continues to serve as the entry point for patients transitioning from oral medications to injectable insulin therapy.
Toujeo, Sanofi’s next-generation insulin glargine at a higher concentration (300 units/mL versus Lantus’s 100 units/mL), represents the evolution. It offers a more stable pharmacokinetic profile , flatter glucose control over 24 hours, with less nocturnal hypoglycemia , and has become an increasingly important part of the Indian portfolio. Together, Lantus and Toujeo give Sanofi a two-tier insulin offering that covers both the cost-sensitive segment and the premium segment of India’s insulin market.
The strategic logic is straightforward: as India’s diabetes population grows and as more patients move from oral therapy to injectables, Sanofi’s insulin franchise is positioned at the intersection of demographic inevitability and therapeutic necessity. It is not a glamorous business. It is an essential one.
Sources: Sanofi India Annual Reports FY2014 through FY2025. Indian Patent Office. BSE India. OPPI.